DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 9.457,071 B2 Hide Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 9.457,071 B2 Hide Et Al US0094.57071B2 (12) United States Patent (10) Patent No.: US 9.457,071 B2 Hide et al. (45) Date of Patent: Oct. 4, 2016 (54) HISTAMINE RELEASER CONTAINED IN 2010/0311604 A1 12/2010 Takkinen et al. HUMAN SWEAT 2011/0117103 A1 5, 2011 Hide et al. 2015,0212097 A1 7/2015 Hide et al. (71) Applicant: Hiroshima University, Higashihiroshima-shi, Hiroshima (JP) FOREIGN PATENT DOCUMENTS EP O955366 A1 11, 1999 (72) Inventors: Michihiro Hide, Hiroshima (JP): EP 16O7107 12/2005 EP 1655.307 A1 5, 2006 Takaaki Hiragun, Hiroshima (JP); EP 229.2659 A1 3, 2011 Kaori Ishii, Hiroshima (JP); Shoji JP 3.642340 A 4/2005 Mihara, Hiroshima (JP); Makiko JP 2008-069 118 A 3, 2008 Hiragun, Hiroshim (JP); Jens-M JP 2010-516747 A 5, 2010 WO 03/084991 A1 10, 2003 Schroeder, Kiel (DE) WO 2005.005474 A1 1, 2005 WO 2008/092993 A1 8, 2008 (73) Assignee: Hiroshima University, Hiroshima (JP) WO 2009,133951 A1 11/2009 (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 OTHER PUBLICATIONS U.S.C. 154(b) by 0 days. Xu et al., “Malassezia globosa CBS 7966 hypothetical protein MGL 1304 partial mRNA.” Database DDBJ/EMBL/GenBank (21) Appl. No.: 14/409,730 online), XM 001731984.1 (2008). Rasool et al., “Cloning, characterization and expression of complete (22) PCT Filed: Jun. 25, 2013 coding sequences of three IgE binding Malassezia furfur allergens, Mal f7. Mal f8 and Mal f 9...” European Journal of Biochemistry, (86). PCT No.: PCT/UP2013/067396 267: 4355-4361 (2000). Lindberg et al., “Malassezia furfur mRNA coding for potential S 371 (c)(1), allergen, strain ATCC No. 42132,” Database DDBJ/EMBL/ (2) Date: Mar. 10, 2015 GenBank online), AJO 11958.1 (2000). Lindberg et al., “Malassezia sympodialis mRNA for allergen Mals (87) PCT Pub. No.: WO2014/003008 8, strain ATCC No. 42132. Database DDBJ/EMBL/GenBank PCT Pub. Date: Jan. 3, 2014 online), AJO1 1958.2 (2002). Kanbe et al., “Atopic Dermatitis and Malassezia Species: A Study (65) Prior Publication Data of Antigenic Components of Malassezia Species for Immunoglobu lin E of Patients with Atopic Dermatitis,” Japanese Journal of US 2015/O238581 A1 Aug. 27, 2015 Medical Mycology, 44: 71-75 (2003) see English abstract. Shindo et al., “Histamine release-neutralization assay for Sera of (30) Foreign Application Priority Data patients with atopic dermatitis and/or cholinergic urticaria is useful to screen type I hyperSensitivity against Sweat antigens.” Archives Jun. 28, 2012 (JP) ................................. 2012-145814 of Dermatological Research, 304: 647-654 (2012). Hiragun et al., “Fungal protein MGL 1304 in Sweat is an allergen (51) Int. Cl. for atopic dermatitis patients,” Journal of Allergy and Clinical GOIN 33/53 (2006.01) Immunology, (2013). A6 IK 39/00 (2006.01) International Search Report issued in corresponding International C07K 16/14 (2006.01) Patent Application No. PCT/JP2013/067396 dated Jul 23, 2013. Steinberger et al., “Construction of a Combinatorial IgE Library GOIN 33/68 (2006.01) from an Allergic Patient.” The Journal of Biological Chemistry, 271: C07K I4/375 (2006.01) 10967-10972 (1996). GOIN 33/569 (2006.01) Tanaka et al., “Cholinergic Urticaria Successfully Treated by A61 K 38/00 (2006.01) Immunotherapy with Partially Purified Sweat Antigen.” Allergy, 56: (52) U.S. Cl. 54-57 (2007) (see English abstract on p. 57). CPC ......... A61K 39/0002 (2013.01); C07K 14/375 (Continued) (2013.01); C07K 16/14 (2013.01); G0IN 33/56961 (2013.01); G0IN 33/6854 (2013.01); A6 IK 38/00 (2013.01); C07K 2317/76 Primary Examiner — Jennifer Graser (2013.01); C07K 2319/30 (2013.01); G0IN (74) Attorney, Agent, or Firm — Morgan, Lewis & 2800/202 (2013.01); G0IN 2800/24 (2013.01) Bockius LLP (58) Field of Classification Search None (57) ABSTRACT See application file for complete search history. Provided are a Sweat allergy antigen, an antibody capable of binding to the antigen specifically, and others, which are (56) References Cited produced utilizing a microorganism-originated protein that U.S. PATENT DOCUMENTS exists in Sweat allergy patient in a dissolved state or a partial peptide of the protein. 2006, OO88926 A1 4/2006 Ozawa et al. 2006/01347.06 A1 6, 2006 Hide et al. 12 Claims, 11 Drawing Sheets US 9.457,071 B2 Page 2 (56) References Cited Xu et al., “hypothetical protein MGL 1304 Malassezia globosa CBS 7966).” RefSeq, online), XP 001732036.1 (2008). OTHER PUBLICATIONS Extended European Search Report issued in corresponding Euro pean Patent Application No. 13809354.7 dated Feb. 10, 2016. Tanaka et al., “Semi-purification of the immunoglobulin E-Sweat Valenta et al., “Autoallergy: A pathogenetic factor in atopic derma antigen acting on mast cells and basophils in atopic dermatitis.” titis?” Journal of Allergy and Clinical Immunology, 105: 432-437 Experimental Dermatology, 15: 283-290 (2006). (2000). Fairley et al., “A Pathogenic Role for IgE in Autoimmunity: Bullous Vilhelmsson, “Structural and functional studies of malassezia Pemphigoid IgE Reproduces the Early Phase of Lesion Develop sympodialis-derived allergens.” Department of Medicine Solna, ment in Human Skin Grafted to nu/nu Mice,” Journal of Investi Clinical Allergy Research Unit, Karolinska Institutet, XP55234699 gative Dermatology, 127: 2605-2611 (2007). Human IgE (non-Immune), BIOPORTO Diagnostics (2011). (2008). International Preliminary Report on Patentability issued in related Partial Supplementary European Search Report issued in related International Patent Application No. PCT/JP2013/071715 dated European Patent Application No. 13879589.3 dated Apr. 20, 2016. Feb. 26, 2015. Ishii et al., “A human monoclonal IgE antibody that binds to International Preliminary Report on Patentability issued in corre MGL 1304, a major allergen in human Sweat, without activation of sponding International Patent Application No. PCT/JP2013/067396 mast cells and basophils.” Biochemical and Biophysical Research dated Dec. 28, 2014. Communications, 468: 99-104 (2015). International Search Report issued in related International Patent “Product Catalog 2010 Bioporto Diagnostics,” XP055257898, Application No. PCT/JP2013/071715 dated Nov. 12, 2013. http://www.ngal.cz/files/bioporto-katalog-2010-en.pdf (2010). U.S. Patent Oct. 4, 2016 Sheet 1 of 11 US 9,457,071 B2 Fig, A B HKMSWGSESPGNVR 0.4 2 15 2 0.3 N N s 1.0 3 0.2 at s s i 0.5 i 0. , 0. 30 35 40 45 50 SS 5 20 25 30 Retension time (min) Retension time (min) as s gits it ge FractioS Fractions Fig.2 C38 stair: anti-his-tag A ser:Fr. U.S. Patent Oct. 4, 2016 Sheet 2 of 11 US 9,457,071 B2 Fig. 3 s 60 mom AD s 50 as AD 2 s 40 ava AD 3 9 30 ara HC 20 : 10 0 a -10 10 100 1000 10000 rMG 1304 (ng/ml) Fig. 4 Ai) sefa A sara Biot A Sea a. rhigi. 304 QRX U.S. Patent Oct. 4, 2016 Sheet 3 of 11 US 9,457,071 B2 Fig.5 -MG 1304 20 U.S. Patent Oct. 4, 2016 Sheet S of 11 US 9,457,071 B2 Fig. 7 5 -25kDa -20kDa in 15kDa "10kba U.S. Patent Oct. 4, 2016 Sheet 6 of 11 US 9,457,071 B2 Fig.9 {x3 Skia Sika 3x33 2Sika ska 28&a 2k}a Sixa ska ka ik}3 Fig. 30 Sit-2 U.S. Patent Oct. 4, 2016 Sheet 7 of 11 US 9,457,071 B2 A. s s 8. s $8 race.823 20 px. 8: s x: staaite release sets 388-8ye-tag ity (R Fig. 2 Difference of reactivity of each MGL-Ab to fragmented rw CL S-3 D3 3-3 A. 3 M E33-3 d E-3 N 33-33 2M g 3 2 Es 3N 2 U.S. Patent Oct. 4, 2016 Sheet 8 of 11 US 9,457,071 B2 Fig. 3 Primary antibody:8-2fantigen: QRX 8x8 x bos Fig. 4 Primary antibody:8-2fantigen:MGL 8.8 88 8. : o: 3. ... 3.3 Fig. 5 Primary antibody:Smith2|antigen:MGL 8 : U.S. Patent Oct. 4, 2016 Sheet 9 of 11 US 9,457,071 B2 Fig. 6 Coating with MGL antibody (6-3) QRX-IgE measurements Dilution of Serur Fig. 7 Coating with MGL antibody (8-2) QRX-lgE measurements . i...................................... ............................ tra-83. Dilution of Serum U.S. Patent Oct. 4, 2016 Sheet 10 of 11 US 9,457,071 B2 Fig.20 MiG-igE x :s 8s Fig.2 : U.S. Patent Oct. 4, 2016 Sheet 11 of 11 US 9,457,071 B2 Fig.22 MGL product ion in M.globosa culture using buffer A ::::::::: Incubation period (min) US 9,457,071 B2 1. 2 HISTAMINE RELEASER CONTAINED IN In one aspect, the present invention provides a composi HUMAN SWEAT tion or kit for detecting an antibody binding to a Sweat allergy antigen, or a composition or kit for measuring an A computer readable text file, entitled “SequenceLis amount of a antigen binding to a Sweat allergy antigen, ting..txt, created on or about Mar. 10, 2015 with a file size comprising a Sweat allergy antigen protein that is a protein of about 15 kb contains the sequence listing for this appli derived from a microorganism or a MGL 1304 partial cation and is hereby incorporated by reference in its entirety. peptide. In one aspect, the present invention provides a composi TECHNICAL FIELD tion or kit for diagnosing a Sweat allergy or a disease related 10 to a Sweat allergy antigen, comprising: This application claims priority to Japanese Patent Appli (i) a Sweat allergy antigen protein that is a protein derived cation No. 2012-145814, filed Jun.
Load more

Recommended publications
  • Results of Accepted Poster
    JSA/WAO Joint Congress 2020 Poster Session As of August 27, 2020 Abstract ID Session Number Abstract No. Seesion Abstract Title Country Efficacy and safety of levamisole as an immunodulator in the treatment of drug resistant 10004 Poster Session 1 PE1-1 Adult airway diseases India tuberculosis Clinical usefulness of serum and sputum YKL-40 in the management of asthma, ACO and 10057 Poster Session 1 PE1-2 Adult airway diseases Japan COPD Exacerbation clusters demonstrate asthma and chronic obstructive pulmonary disease 10203 Poster Session 1 PE1-3 Adult airway diseases Japan (COPD) overlap with distinct phenotypes 10289 Poster Session 1 PE1-4 Adult airway diseases Anti-allergy medication utilization in patients with Chronic Cough United States of America 10299 Poster Session 1 PE1-5 Adult airway diseases Burden of Persistent Chronic Cough in Adults in a Large Managed Care Organization United States of America Degree of skin moisture in allergic diseases varies according to complication of airway 10434 Poster Session 1 PE1-6 Adult airway diseases Japan diseases Baseline characteristics from Phase 3, randomized controlled trials (COUGH-1 and COUGH- 10538 Poster Session 1 PE1-7 Adult airway diseases United States of America 2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough Allergen avoidance clinical trial: correlation of symptom scores between 4 and 6 point 10711 Poster Session 1 PE1-8 Adult airway diseases Bulgaria scoring systems Comparison of diffusion capacity and bronchodilator responsiveness testing
    [Show full text]
  • High Histamine Concentrations in Human Sweat in Association with Type I Allergy to the Semi-Purified Sweat Antigen
    Allergology International 69 (2020) 307e309 Contents lists available at ScienceDirect Allergology International journal homepage: http://www.elsevier.com/locate/alit Letter to the Editor High histamine concentrations in human sweat in association with type I allergy to the semi-purified sweat antigen Dear Editor, To find bioactivity of histamine detected in sweat, we assessed concentrations of histamine to induce flare and wheal by the intra- Cholinergic urticaria (CholU) is characterized by pinpoint-sized dermal injection to healthy volunteers, and compared with hista- wheals with itching and/or stinging pain under sweating mine concentrations in sweat. Histamine concentrations at or conditions, including hot bathing, physical exercise and emotional higher than 100 ng/ml and 1000 ng/ml induced significant flare stress.1 The type I hypersensitivity to sweat is proposed to be and wheal formations (Fig. 2a,b). In four patients with CholU, a pa- involved in its pathogenesis.2 Indeed, more than 60% of patients tient with AD and three controls, sweat histamine concentrations with CholU shows immediate-type skin reactions upon intradermal were higher than the minimum concentration to induce flare injection of autologous sweat, and histamine release from baso- upon intradermal injection (100 ng/ml). In one patient with phils against the semi-purified sweat antigen in histamine release CholU and one control, they were high enough even for wheal assay (HRA).2,3 Histamine released from skin mast cells also plays induction (1000 ng/ml). an important role in the development of wheals in CholU.1 In this In this study, we demonstrated that levels of histamine con- study, we examined histamine concentrations in sweat of patients centration in sweat obtained from patients with CholU were with CholU to describe a role of sweat histamine in the wheal for- much higher than those in human plasma.
    [Show full text]
  • Ige-Mediated Hypersensitivity Against Human Sweat Antigen in Patients with Atopic Dermatitis
    Acta Derm Venereol 2002; 82: 335± 340 INVESTIGATIVE REPORT IgE-mediated Hypersensitivity Against Human Sweat Antigen in Patients with Atopic Dermatitis MICHIHIRO HIDE, TOSHIHIKO TANAKA, YUMI YAMAMURA, OSAMU KORO and SHOSO YAMAMOTO Department of Dermatology, Programs for Biomedical Research, Division of Molecular Medical Science, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan Sweating aggravates itch in atopic dermatitis, but the a bath, is largely bene® cial to patients (1, 5), and mechanism is unclear. In this study, we examined the suggests the presence of aggravating factors on the skin involvement of type I hypersensitivity in the aggravation surface. On the other hand, immediate-type skin of atopic dermatitis by sweating. Skin tests with auto- reactions to human dander extracts (6, 7) and human logous sweat were positive in 56 of 66 patients (84.4%) sweat (8, 9) have been reported in patients with atopic with atopic dermatitis, but only in 3 of 27 healthy volun- dermatitis. Adachi & Aoki (9) showed the binding teers (11.1%). Sweat samples from both patients and activity of IgE antibody against sweat concentrate healthy volunteers induced varying degrees of histamine collected from a healthy volunteer in patients with release from basophils of patients with atopic dermatitis. atopic dermatitis. More recently, Valenta et al. (10) and However, the histamine release was impaired by removal Natter et al. (11) have identi® ed several intracellular of IgE on the basophils. Incubation of basophils with autoantigens for IgE antibodies in the sera of patients myeloma IgE before sensitization with serum of patients with severe skin manifestations of atopic dermatitis.
    [Show full text]
  • 10 Chronic Urticaria As an Autoimmune Disease
    10 Chronic Urticaria as an Autoimmune Disease Michihiro Hide, Malcolm W. Greaves Introduction Urticaria is conventionally classified as acute, intermittent and chronic (Grea- ves 2000a). Acute urticaria which frequently involves an IgE-mediated im- munological mechanism, is common, its causes often recognised by the patient, and will not be considered further. Intermittent urticaria – frequent bouts of unexplained urticaria at intervals of weeks or months – will be dis- cussed here on the same basis as ‘ordinary’ chronic urticaria. The latter is conventionally defined as the occurrence of daily or almost daily whealing for at least six weeks. The etiology of chronic urticaria is usually obscure. The different clinical varieties of chronic urticaria will be briefly considered here, and attention will be devoted to a newly emerged entity – autoimmune chronic urticaria, since establishing this diagnosis has conceptual, prognostic and the- rapeutic implications. Contact urticaria and angioedema without urticaria will not be dealt with in this account. Classification of Chronic Urticaria The clinical subtypes of chronic urticaria are illustrated in the pie-chart of Fig. 1. The frequency of these subtypes is based upon the authors’ experience at the St John’s Institute of Dermatology in UK. Whilst there may well be mi- nor differences, it is likely that the frequency distribution of these subtypes will be essentially similar in most centres in Europe and North America (Grea- ves 1995, 2000b). However, our experience suggests that the incidence of angioedema, especially that complicated by ordinary chronic urticaria is sub- stantially lower in Japan and south Asian countries (unpublished observation). 310 Michihiro Hide and Malcolm W.
    [Show full text]
  • A Case of Cold-Induced Cholinergic Urticaria Accompanied by Cholinergic Urticaria Showing a Positive Ice Cube Test
    Allergology International 69 (2020) 150e151 Contents lists available at ScienceDirect Allergology International journal homepage: http://www.elsevier.com/locate/alit Letter to the Editor A case of cold-induced cholinergic urticaria accompanied by cholinergic urticaria showing a positive ice cube test Dear Editor, eyelids, erythema of the face and generalized pruritic wheals, fol- lowed by sweating (Fig. 1A). The wheals disappeared spontane- Cholinergic urticaria (CholU) is a frequent form of inducible ur- ously within an hour. Results of a quantitative Sudomotor Axon ticaria provoked after sweating due to various stimuli that increase Reflex Test revealed a normal sweating function, and cholinergic the core body temperature, such as exercise, hot bathing, emotional urticaria with acquired anhidrosis or hypohidrosis was denied. In- stress and thermal environment.1 Its clinical features include itchy, tradermal injection of acetylcholine into the volar aspect of the pinpoint-sized wheals and surrounding erythema, and the symp- forearm showed numerous pin-point hives around the injection toms are often worse in hot summer weather. Although the precise site (Fig. 1B). In an autologous sweat skin test using her sweat mechanisms are not completely understood, IgE-mediated mast collected during sauna bathing, the result was positive for 100- cell activation and histamine release is extremely important in fold diluted sweat with wheal diameters of 6 Â 7 mm accompanied the pathogenesis of CholU. Patients with CholU frequently show by a flare reaction. The diagnosis of CholU with sweat hypersensi- an atopic background and have sweat allergy with specific IgE tivity was therefore made. against a protein from Malassezia globosa, a major allergen con- She also complained of developing wheals in cold environments tained in human sweat.2 Cold-induced CholU is a rare phenomenon without any sweating stimulus.
    [Show full text]
  • Exacerbating Factors of Itch in Atopic Dermatitis
    Allergology International xxx (2016) 1e6 Contents lists available at ScienceDirect Allergology International journal homepage: http://www.elsevier.com/locate/alit Invited review article Exacerbating factors of itch in atopic dermatitis * Hiroyuki Murota , Ichiro Katayama Department of Dermatology, Course of Integrated Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan article info abstract Article history: Atopic dermatitis (AD) displays different clinical symptoms, progress, and response to treatment during Received 12 September 2016 early infancy and after childhood. After the childhood period, itch appears first, followed by formation of Received in revised form well-circumscribed plaque or polymorphous dermatoses at the same site. When accompanied with 11 October 2016 dermatitis and dry skin, treatment of skin lesions should be prioritized. When itch appears first, disease Accepted 12 October 2016 history, such as causes and time of appearance of itch should be obtained by history taking. In many Available online xxx cases, itch increases in the evening when the sympathetic nerve activity decreased. Treatment is pro- vided considering that hypersensitivity to various external stimulations can cause itch. Heat and Keywords: Atopic dermatitis sweating are thought to especially exacerbate itch. Factors causing itch, such as cytokines and chemical Exacerbating factors messengers, also induce itch mainly by stimulating the nerve. Scratching further aggravates dermatitis. Itch Skin hypersensibility, where other non-itch senses, such as pain and heat, are felt as itch, sometimes Life rhythm occurs in AD. Abnormal elongation of the sensory nerve into the epidermis, as well as sensitizing of the Pruritus peripheral/central nerve, are possible causes of hypersensitivity, leading to itch. To control itch induced by environmental factors such as heat, treatment for dermatitis is given priority.
    [Show full text]
  • Sensitization Against Skin Resident Fungi Is Associated with Atopy In
    Altrichter et al. Clin Transl Allergy (2020) 10:18 https://doi.org/10.1186/s13601-020-00324-z Clinical and Translational Allergy RESEARCH Open Access Sensitization against skin resident fungi is associated with atopy in cholinergic urticaria patients Sabine Altrichter1 , Pia Schumacher1, Ola Alraboni1, Yiyu Wang1, Makiko Hiragun2, Michihiro Hide2 and Marcus Maurer1* Abstract Background: Cholinergic urticaria (CholU) is a common type of chronic inducible urticaria, characterized by small itchy wheals that appear upon physical exercise or passive warming. Malassezia globosa, a skin resident fungus, has been identifed as an antigen that induces mast cell/basophil degranulation and wheal formation through specifc IgE, in Japanese patients with atopic dermatitis and CholU. In this study we aimed in assessing the rate of IgE sensiti- zations against skin resident fungi in European CholU patients. Methods: We assessed serum IgE levels to Malassezia furfur, Candida albicans and Trichophyton mentagrophytes using routine lab testing and Malassezia globosa using a newly established ELISA. We correlated the results to wheal forma- tion and other clinical features. Results: Four patients (of 30 tested) had elevated levels of IgE against Malassezia furfur and Candida albicans and two had elevated levels of IgE against Trichophyton mentagrophytes. Four sera (of 25 tested) had elevated levels of IgE to the Malassezia globosa antigen supMGL_1304. Sensitization to one skin fungus was highly correlated with sensitiza- tion to the other tested fungi. We saw highly signifcant correlations of sensitization to supMGL_1304 with wheal size in the autologous sweat skin test (r 0.7, P 0.002, n 19), the Erlangen atopy score (r 0.5, P 0.03, n 19), total s = = = s = = = IgE serum levels (rs 0.5, P 0.04, n 19) and a positive screen for IgE against common airborne/inhalant allergens s (sx1; r 0.54, P 0.02,= n =19).
    [Show full text]
  • A Descriptive Study of Naadi Thervu and Its Clinical Features Based on the Text “Sadhaga Naadi”
    A DESCRIPTIVE STUDY OF NAADI THERVU AND ITS CLINICAL FEATURES BASED ON THE TEXT “SADHAGA NAADI” DISSERTATION SUBMITTED BY Dr. S. PRANAV DHEENATHAYALAN (Reg.No.321615003) TO THE TAMIL NADU DR. M.G.R. MEDICAL UNIVERSITY CHENNAI – 32 For the Partial fulfillment for Award of the Degree of DOCTOR OF MEDICINE (SIDDHA) (Branch V – P.G. NOI NAADAL) DEPARTMENT OF NOI NADAL GOVERNMENT SIDDHA MEDICAL COLLEGE PALAYAMKOTTAI – 627 002. OCTOBER - 2019 GOVERNMENT SIDDHA MEDICAL COLLEGE AND HOSPITAL, PALAYAMKOTTAI, TIRUNELVELI - 627002, TAMIL NADU, INDIA. Ph: 0462-2572736/2572737/2582010 Fax: 0462 2582010 DECLARATION BY THE CANDIDATE I hereby declare that this dissertation entitled A DESCRIPTIVE STUDY OF NAADI THERVU AND ITS CLINICAL FEATURES BASED ON THE TEXT “SADHAGA NAADI” is a bonafide and genuine research work done by me under the guidance and supervision of Prof. Dr. R. Neelavathy, MD(s)., Ph.D., Post Graduate Department of Noi Naadal, Government Siddha Medical College and Hospital, Palayamkottai and the dissertation has not formed the basis for the award of any other Degree, Diploma, Fellowship or other similar title. Date : Place : Signature of the Candidate Dr. S. Pranav Dheenathayalan GOVERNMENT SIDDHA MEDICAL COLLEGE AND HOSPITAL, PALAYAMKOTTAI, TIRUNELVELI - 627002, TAMIL NADU, INDIA. Ph: 0462-2572736/2572737/2582010 Fax: 0462 2582010 DECLARATION BY THE CANDIDATE I hereby declare that this dissertation entitled A DESCRIPTIVE STUDY OF NAADI THERVU AND ITS CLINICAL FEATURES BASED ON THE TEXT “SADHAGA NAADI” is a bonafide and genuine research work done by me under the guidance and supervision of Prof. Dr. S. Victoria, MD(s). , Post Graduate Department of Noi Naadal, Government Siddha Medical College and Hospital, Palayamkottai and the dissertation has not formed the basis for the award of any other Degree, Diploma, Fellowship or other similar title.
    [Show full text]
  • Ige Autoreactivity in Atopic Dermatitis: Paving the Road for Autoimmune Diseases?
    antibodies Review IgE Autoreactivity in Atopic Dermatitis: Paving the Road for Autoimmune Diseases? Christophe Pellefigues INSERM UMRS1149—CNRS ERL8252, Team «Basophils and Mast cells in Immunopathology», Centre de recherche sur l’inflammation (CRI), Inflamex, DHU Fire, Université de Paris, 75018 Paris, France; Christophe.pellefi[email protected] Received: 5 August 2020; Accepted: 4 September 2020; Published: 8 September 2020 Abstract: Atopic dermatitis (AD) is a common skin disease affecting 20% of the population beginning usually before one year of age. It is associated with the emergence of allergen-specific IgE, but also with autoreactive IgE, whose function remain elusive. This review discusses current knowledge relevant to the mechanisms, which leads to the secretion of autoreactive IgE and to the potential function of these antibodies in AD. Multiple autoantigens have been described to elicit an IgE-dependent response in this context. This IgE autoimmunity starts in infancy and is associated with disease severity. Furthermore, the overall prevalence of autoreactive IgE to multiple auto-antigens is high in AD patients. IgE-antigen complexes can promote a facilitated antigen presentation, a skewing of the adaptive response toward type 2 immunity, and a chronic skin barrier dysfunction and inflammation in patients or AD models. In AD, skin barrier defects and the atopic immune environment facilitate allergen sensitization and the development of other IgE-mediated allergic diseases in a process called the atopic march. AD is also associated epidemiologically with several autoimmune diseases showing autoreactive IgE secretion. Thus, a potential outcome of IgE autoreactivity in AD could be the development of further autoimmune diseases. Keywords: atopic dermatitis; autoreactive IgE; IgE; autoimmunity; basophil 1.
    [Show full text]
  • Malassezia-Associated Skin Diseases, the Use of Diagnostics and Treatment
    Malassezia-Associated Skin Diseases, the Use of Diagnostics and Treatment Saunte, Ditte M.L.; Gaitanis, George; Hay, Roderick James Published in: Frontiers in Cellular and Infection Microbiology DOI: 10.3389/fcimb.2020.00112 Publication date: 2020 Document version Publisher's PDF, also known as Version of record Document license: CC BY Citation for published version (APA): Saunte, D. M. L., Gaitanis, G., & Hay, R. J. (2020). Malassezia-Associated Skin Diseases, the Use of Diagnostics and Treatment. Frontiers in Cellular and Infection Microbiology, 10, [112]. https://doi.org/10.3389/fcimb.2020.00112 Download date: 24. sep.. 2021 REVIEW published: 20 March 2020 doi: 10.3389/fcimb.2020.00112 Malassezia-Associated Skin Diseases, the Use of Diagnostics and Treatment Ditte M. L. Saunte 1,2*†, George Gaitanis 3,4†‡ and Roderick James Hay 5† 1 Department of Dermatology, Zealand University Hospital, Roskilde, Denmark, 2 Department of Clinical Medicine, Health Sciences Faculty, University of Copenhagen, Copenhagen, Denmark, 3 Department of Skin and Venereal Diseases, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece, 4 DELC Clinic, Biel/Bienne, Switzerland, 5 St. Johns Institute of Dermatology, Kings College London, London, United Kingdom Edited by: Yeasts of the genus, Malassezia, formerly known as Pityrosporum, are lipophilic yeasts, Salomé LeibundGut-Landmann, which are a part of the normal skin flora (microbiome). Malassezia colonize the human University of Zurich, Switzerland skin after birth and must therefore, as commensals, be normally tolerated by the Reviewed by: Peter Mayser, human immune system. The Malassezia yeasts also have a pathogenic potential where University of Giessen, Germany they can, under appropriate conditions, invade the stratum corneum and interact with Philipp Peter Bosshard, the host immune system, both directly but also through chemical mediators.
    [Show full text]
  • Pathogenesis of Cholinergic Urticaria in Relation to Sweating Toshinori Bito1, Yu Sawada2 and Yoshiki Tokura3
    Allergology International. 2012;61:539-544 ! DOI: 10.2332 allergolint.12-RAI-0485 REVIEW ARTICLE Review Series: Advances in Consensus, Pathogenesis and Treatment of Urticaria and Angioedema Pathogenesis of Cholinergic Urticaria in Relation to Sweating Toshinori Bito1, Yu Sawada2 and Yoshiki Tokura3 ABSTRACT Cholinergic urticaria (CU) has clinically characteristic features, and has been frequently described in the litera- ture. However, despite its comparatively old history, the pathogenesis and classification remains to be clarified. CU patients are occasionally complicated by anhidrosis and!or hypohidrosis. This reduced-sweat type should be included in the classification because the therapeutic approaches are different from the ordinary CU. It is also well-known that autologous sweat is involved in the occurrence of CU. More than half of CU patients may have sweat hypersensitivity. We attempt to classify CU and address the underlying mechanisms of CU based on the published data and our findings. The first step for classification of CU seems to discriminate the pres- ence or absence of hypersensitivity to autologous sweat. The second step is proposed to determine whether the patients can sweat normally or not. With these data, the patients could be categorized into three subtypes: (1) CU with sweat hypersensitivity; (2) CU with acquired anhidrosis and!or hypohidrosis; (3) idiopathic CU. The pathogenesis of each subtype is also discussed in this review. KEY WORDS acetylcholine, acetylcholine receptor, anhidrosis, hypohidrosis, sweat hypersensitivity choline. In fact, acetylcholine stimulation can elicit INTRODUCTION hives as seen in CU, suggesting that the etiology of Cholinergic urticaria (CU) is a rare condition, but its CU includes certain events that are triggered by a incidence might be higher than that expected by gen- cholinergic stimulus.
    [Show full text]
  • URTICÁRIA Da Clínica À Terapêutica
    URTICÁRIA da Clínica à Terapêutica URTICÁRIA da Clínica à Terapêutica editor Celso Pereira © Autor Merck Sharpe & Dohme (MSD) Título: Urticária da Clínica à Terapêutica Editor: Celso Pereira Imagem da capa: Arq Pedro Rodrigues (Coimbra) Design e Produção Gráfica: Nastintas – Design e Comunicação (Lisboa) Impressão: Offsetmais Artes Gráficas, S.A. ISBN: 978-989-96725-0-5 Depósito Legal: XXXXX Tiragem: 8000 exemplares Data de edição: Maio 2010 Reservados todos os direitos. Sem prévio consentimento da editora, não poderá reproduzir-se, nem armazenar-se num suporte recuperável ou transmissível, nenhuma parte desta publicação, seja de forma electrónica, mecânica, fotocopiada, gravada ou por qualquer outro método. Todos os comentários e opiniões publicados neste livro são de responsabilidade exclusiva dos seus autores. “Nesta nossa profissão, como muito bem sabem quantos a exercem, podem acontecer milagres e até se diz que a Medicina tem muito de Divino, mas temos que estar sempre atentos a todos os pormenores e aos mais pequenos sinais.” In Curationum Medicinalium Centuriae Septem Amatus Lusitanus (1511-1568) VII NOTA INTRODUTÓRIA O uso eficiente e disciplinado da informação e do conhe- cimento científico são valores essenciais para a evolução da prática da Medicina. A aplicação eficiente de conhecimentos médicos actua- lizados exige uma gestão criteriosa da informação que é disponibilizada e divulgada diariamente Neste contexto, é indiscutível a necessidade e a pertinên- cia da disponibilização de guias de orientação e padrões de actuação, que se traduzem no contexto das boas práticas em Normas Orientadoras de Diagnóstico e Tratamento. Apesar de não se tratar de uma doença de elevada prevalência, a Urticária tem um impacto significativo na qualidade de vida dos doentes, constituindo um desafio pela sua diversidade etiológica, formas de apresentação e consequente complexidade de diagnóstico e abordagem terapêutica.
    [Show full text]